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Abstract
Coated vesicles mediate the traffic of secretory and membrane cargo proteins from the endoplasmic reticulum (ER) to the
Golgi apparatus. The coat protein complex (COPII) involved in vesicle budding is constituted by a GTPase, Sar1, the inner
coat components of Sec23/Sec24 and the components of the outer coat Sec13/Sec31A. The Ca2+-binding protein ALG-2 was
recently identified as a Sec31A binding partner and a possible link to Ca2+ regulation of COPII vesicle budding. Here we
show that ALG-2/Ca2+ is capable of attenuating vesicle budding in vitro through interaction with an ALG-2 binding domain
in the proline rich region of Sec31A. Binding of ALG-2 to Sec31A and inhibition of COPII vesicle budding is furthermore
dependent on an intact Ca2+-binding site at EF-hand 1 of ALG-2. ALG-2 increased recruitment of COPII proteins Sec23/24
and Sec13/31A to artificial liposomes and was capable of mediating binding of Sec13/31A to Sec23. These results introduce
a regulatory role for ALG-2/Ca2+ in COPII tethering and vesicle budding.
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Introduction
Ca2+ is a ubiquitous messenger molecule regulating a wide array
of cell biological processes. Recent evidence suggests that Ca2+
transients may also be involved in regulatory mechanisms related
to protein trafficking. The Ca2+ binding protein ALG-2 (product
of the apoptosis linked gene-2) was found to interact with Sec31A,
a component of the coat protein complex II (COPII) in a Ca2+-
dependent manner. It has thus been speculated that ALG-2
mediates a Ca2+-link to COPII dependent protein traffic [1,2,3].
During physiological Ca2+ transients a major part of the cytosolic
ALG-2 redistributes to cytoplasmic puncta [1] where it colocalizes
with Sec31A [1,2,3] and the ER exit site marker p125 [3]. Ca2+
signaling has been shown to be mandatory for some aspects of
vesicle trafficking such as synaptotagmin-mediated membrane
fusion [4]. Furthermore, recent work by Bentley et al. suggests that
Ca2+ together with ALG-2 plays a regulatory role in the fusion of
COPII vesicles after budding [5]. ALG-2 was originally assigned a
functional role in apoptosis linking Ca2+ signaling to programmed
cell death [6], however, no molecular mechanism underlying this
function has been described. In addition, the suggested apoptotic
function of ALG-2 was not confirmed by gene knock out studies in
mice [7].
Protein export from the ER is facilitated by vesicles encaged by
the Sar1, Sec23–Sec24 and Sec13–Sec31 proteins constituting a
COPII vesicle (reviewed in [8]) Defects in COPII component
expression were found to lead to skeletal abnormalities [9] and
improper extracellular matrix formation [10]. Structural data
suggests a COPII cage diameter size of 60–80 nm [11],
contrasting with findings of COPII-dependent export of collagen
[12], which would require larger vesicles (reviewed in [13]). This
has led to speculation that a specialized mechanism to accommo-
date bulky cargo is needed, and evidence supporting this has come
with the recent discovery of a role for ubiquitin conjugation of
Sec31 in the formation of enlarged COPII- vesicles facilitating
collagen export [14]. How the COPII structures are retained at
the ER exit sites in order to expand to a size large enough to
accommodate bulk cargo remains unexplained. Here we show that
Ca2+-ALG-2 attenuates the exit of protein from the ER through
an interaction with the proline rich region of Sec31A. Further-
more, we find that ALG-2 in vitro is capable of bridging the outer
and inner components, Sec31A and Sec23 of COPII.
Results
ALG-2 Inhibits in vitro Budding in a Ca2+-dependent
Manner
ALG-2 was previously described to interact with Sec31A in a
Ca2+-dependent manner [1,2,3]. However, the significance of this
interaction for ER to Golgi protein transport is not seen in the
trafficking of VSV-G in cells depleted of ALG-2 [3]. In order to
test the effect of ALG-2 on COPII budding under controlled Ca2+-
conditions, we investigated the consequences of adding recombi-
nant ALG-2 to a cell-free vesicle budding reaction in the presence
or absence of free Ca2+. Using two transit cargo marker proteins,
the SNARE protein Sec22b and the ER-Golgi cargo protein p58/
ERGIC, we were able to measure the efficiency of COPII-
dependent vesicle budding. Increasing Ca2+ concentrations
(Figure 1, data points 4–9) correlated with decreased budding
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efficiency, which was further decreased in the presence of
recombinant ALG-2 (Figure 1, data points 10–13). Ca2+ inhibited
budding starting at concentrations greater than 1.2 mM, whereas
addition of recombinant ALG-2 inhibited budding at a lower
concentration of 300 uM Ca2+. Non-physiological concentrations
of Ca2+ were used to override the Ca2+ chelator EGTA from the
rat liver cytosol preparations. Mutant versions of ALG-2 that are
partially deficient in Ca2+-binding led to a partial recovery of the
budding efficiency at elevated Ca2+ concentration most promi-
nently when EF hand 1 was inactivated by mutation (Figure 1,
data points 14 and 15). The inhibitory effect of wild-type ALG-2
was abolished when further EGTA was added (Figure 1, data
points 17 and 19), demonstrating that ALG-2 requires Ca2+ for its
effect on budding. In all conditions, budding was sharply reduced
in incubations containing a dominant negative form of the COPII
protein Sar1p (Sar1H79G, Figure 1, data points 3, 16 and 20),
showing the requirement for functional COPII in the budding
reaction.
ALG-2 Acts Directly on COPII to Inhibit Vesicle Budding in
a Reversible Manner
To avoid the presence of chelator and auxiliary factors present
in the liver cytosol that could interfere with the ALG-2/Ca2+ effect
on budding (Figure 1), we reconstituted the budding assay with
pure recombinant Sar1A, Sec23A/24D, and Sec13/31A in place
of cytosol [15]. We found that ALG-2/Ca2+ acted directly through
COPII and using various concentrations of both ALG-2 and Ca2+
found that budding was inhibited when the molar ratio of ALG-2
to Sec31A exceeded 2:1 (Figure 2A). In this reconstitution,
budding was inhibited by ALG-2 even when no Ca2+ was added,
indicating that in the absence of chelator, background Ca2+ levels
from the donor membrane preparations are sufficient to inhibit
budding in concert with ALG-2 (Figure 2A). It was previously
shown that ALG-2 redistribution from the cytosol to ER exit site
structures is observed following induction of Ca2+ transients with
histamine or other stimuli [1]. Ca2+ binds to the high affinity EF
hands 1 and 3 of ALG-2 with a KD of 1.3 mM [16], which is
within the range of the Ca2+-levels reached during cellular Ca2+
transients evoked by histamine [17]. To ensure that free Ca2+ was
Figure 1. ALG-2 attenuates COPII dependent budding. The budding efficiency was measured from the amount of p58 and Sec22b in vesicles
relative to the amount in donor membranes. HeLa cell donor membranes were incubated with rat liver cytosol, ATP and an ATP regenerating system,
and wild-type recombinant ALG-2 (lanes 10–13) or ALG-2 with mutant versions of either EF-hand 1 (ALG2EF1, lane 14) or EF-hand 3 (ALG2EF3, lane
15) in the presence of either Ca2+ (lanes 6–16) or chelator (EGTA, lanes 17–20). As controls, membranes were incubated in the absence of either
nucleotides (No NT, lane 1) or cytosol (No cyt, lane 2). As a control for the requirement of COPII proteins, we performed assays in the presence of a
GTP-restricted dominant-negative form of the GTPase Sar1, Sar1 (H79G, lanes 3, 16 and 20). Budding efficiency was measured from band intensities
and normalized to the amount of budding in the no Ca2+, no ALG-2 vesicle budding (0 Ca, lane 4) reaction. Bars indicate average +/2 SD of three
independent experiments.
doi:10.1371/journal.pone.0075309.g001
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available for activation of ALG-2, we added 10 mM Ca2+ to the
in vitro reconstituted budding assay unless otherwise stated. To
investigate the partial inhibitory effect of the ALG-2 EF hand
mutants in budding, we performed binding studies by incubating
recombinant ALG-2 versions with His-tagged Sec31A immobi-
lized on Nickel-beads. In the presence of Ca2+, only the splice
variant of ALG-2, ALG-2.1 [16], and ALG-2 with the E114A
substitution in EF-hand 3 were able to bind to Sec31A (Figure 2B),
indicating that EF1-hand 1 is mandatory for this interaction.
Furthermore, using the ALG-2 mutants in the budding assay, we
showed that the binding capacity of the ALG-2 versions correlated
with their ability to inhibit budding in a Ca2+-dependent manner
(Figure 2C). This indicates that an EF-hand1-dependent binding
of ALG-2 to Sec31A is associated with the Ca2+-mediated
inhibition of vesicle budding. To support the proposed correlation
between the binding of ALG-2 and Sec31A with budding
inhibition and the Ca2+-dependent oscillatory pattern of ALG-2
distribution in the microscopy experiments, we performed the
budding reaction in the presence of exogenous Ca2+. EGTA was
added after 15 and 30 min to remove Ca2+ in order to allow
disruption of the ALG-2/Sec31A complex. Following addition of
EGTA, the budding efficiency was restored in the reactions where
ALG-2 was present (Figure 2D), suggesting that Ca2+ chelation
abolishes the ALG-2 attenuation of COPII vesicle budding. To
identify possible changes in vesicular budding products as a
consequence of adding ALG-2, we resolved membranes in the
budding reaction on a Nycodenz buoyant density gradient and
fractions were analyzed for the presence of the budding marker
p58/ERGIC. In the presence of ALG-2, only trace amounts of
p58/ERGIC were found as compared to control conditions in
which p58/ERGIC was found in light vesicle fractions (Figure 2E).
The resident ER marker protein ribophorin I, which is retained in
the ER, was undetectable in the fractions (not shown). These
findings indicate that vesicles containing marker cargo do not bud
from the ER in the presence of ALG-2/Ca2+.
The Inhibitory Effect of ALG-2 on Budding is Mediated
through Sec31A
To investigate whether the inhibitory effect of ALG-2 was
mediated through an interaction with Sec31A, we mapped the
ALG-2 interaction site on Sec31A using a peptide array
(Figure 3A). The mapped ALG-2 target sequence (Figure 3B)
corresponded to the ALG-2 binding site at amino acids 839–851
recently described by Shibata et al. [18]. Deletion of amino acids
827–852 of Sec31A led to abrogation of ALG-2 binding. The
relative molar ratio of components collected using Ni beads and
His-tagged Sec31A was estimated from fluorescence intensity
readings to be 1:1:2 for Sec13:Sec31A:ALG-2 for wild type
Sec31A whereas only background levels of ALG-2 were seen in the
case of Sec31A lacking the ALG-2 binding domain (Sec31Amu-
tABD) (Figure 3C). Vesicle budding could be reconstituted when
the wt recombinant Sec31A was substituted with the version
lacking the ALG-2 binding domain indicating that the Sec31A-
delABD is biologically active. Furthermore, we were able to
reverse the inhibitory effect of ALG-2 by using the Sec31AdelABD
in place of the wt Sec31A (Figure 3D) indicating that ALG-2 is
acting directly through Sec31A to inhibit vesicle budding. We
found that excess ALG-2 overcame the reversible budding
inhibition of the Sec31AdelABD indicating a Sec31A-independent
function for ALG-2 on the budded vesicles (Figure 3E). This could
be due to an effect of ALG-2 on the fusogenicity of transport
vesicles as described previously [5].
ALG-2 Connects the Inner and Outer Coat of COPII
in vitro
In order to test whether ALG-2 was recruited along with the
COPII complex on artificial liposomes [19], ALG-2 and COPII
proteins were mixed with liposomes and then resolved by buoyant
density gradient flotation. We found that in the presence of Ca2+
and ALG-2, both Sec23A/Sec24D and Sec13/31A were recruited
to the liposomes to a higher extent than in the absence of ALG-2
(Figure 4A). Adding EGTA reversed this ALG-2-dependent
recruitment and the recruitment was significantly diminished by
the presence of a peptide representing the ALG-2 binding site of
Sec31A, indicating that the recruitment of the COPII components
was dependent on ALG-2 binding to Sec31A. Quantifying the
protein band intensities relative to a 10–200 ng COPII recombi-
nant protein standard (Figure S2), we found that the inner and
outer coat proteins increased in the presence of ALG-2/Ca2+ but
the levels of Sar1 appeared constant (Figure 4B) indicating that
ALG-2 is capable of accumulating Sec23/24 and Sec13/31 to
membranes irrespective of Sar1. To test whether ALG-2 could
mediate binding of the outer COPII coat to the inner coat, we
used flag-tagged Sec23A in complex with Sec24D as bait for the
recruitment of Sec13/31A. Sec13/31A was recruited only in the
presence of ALG-2/Ca2+ whereas the version of Sec31A with
ABD deleted was not recruited. This was the case also for the
Sec23B isoform in complex with Sec24D (Fig. 4C) as well as for
Sec23A in complex with the Sec24A and Sec24C isoforms (not
shown). Furthermore, we found that Sec23A itself was sufficient to
recruit Sec13/31A in the presence of ALG-2/Ca2+. ALG-2 was
only recruited in the presence of Sec31A suggesting that ALG-2
binding alters Sec31A to enable it to bind Sec23A rather than
binding both Sec23 and Sec31A (Fig. 4C).
Discussion
Though much is known about the molecules involved in
transporting cargo from the ER to the Golgi (reviewed in [20],
little is known about the role of possible cationic regulation of this
process. We have identified ALG-2 and Ca2+ as novel regulators of
the COPII budding process. ALG-2 inhibited the capture of
membrane cargo proteins Sec22 and p58/ERGIC into vesicles in
a cell-free COPII reaction, which reproduces the sorting of
transport cargo that bud from the ER. This vesicle budding
inhibition is mediated through an ALG-2/Ca2+ dependent
binding of Sec31A. ALG-2/Ca2+ also mediates binding of Sec31A
to Sec23 in the inner layer of the coat. This connection may
interfere with cargo sorting by the Sec23/24 heterodimer.
The group of JC Hay previously described that ALG-2/Ca2+
inhibited heterotrimerization of a COPII membrane cargo
protein, VSV-G protein, an assay they developed to quantify
vesicle fusion [21]. They concluded that ALG-2/Ca2+ might block
vesicle fusion to a target membrane by causing COPII to be
retained on transport vesicles [5]. In our experiments ALG-2/
Ca2+ inhibits budding though it may also block COPII vesicle
targeting and fusion. Exceeding a 2:1 molar ratio of ALG-
2:Sec31A caused a Sec31A-independent block of budding, in that
the Sec31AdelABD mutant did not restore budding inhibited by
ALG-2 (Figure 3E). The Hay group found that the Ca2+-binding
sites of ALG-2 were important for inhibition of fusogenicity,
however, the molecular target of this ALG-2/Ca2+-dependent
inhibition was not experimentally addressed [5]. In our experi-
ments we have minimized the effect of both auxiliary factors in
COPII budding as well as endogenous ALG-2 found in liver
cytosol by reconstituting the COPII budding process with purified
proteins. The membrane cargo protein p58/ERGIC was detected
ALG-2 Attenuates Vesicle Budding
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in vesicles produced in normal reactions but little or no cargo
protein was detected in reactions containing ALG-2 (Figure 2E,
Figure S1).
Previous work documented a Ca2+-dependent co-localization of
ALG-2 with Sec31A possibly at the ER exit sites [1,2,3]. Depletion
of ALG-2 in HeLa cells reduced the localization of Sec31A in
membranes and correspondingly the depletion of Sec31A
decreased ALG-2 in a membrane fraction [3]. The precise site
of interaction of Sec31A with ALG-2 has not yet been identified.
Based on crystal structure studies of ALG-2 it was suggested that a
conformational change induced by Ca2+ binding would expose a
hydrophobic crevice on the surface of ALG-2 by rotation of the
masking an arginine (R125) allowing interaction with a peptide
representing Alix/AIP1 [22]. Unlike Alix/AIP1, Sec31A binds to
the alternative splice variant ALG-2.1 (Figure 2A) [23,24]. This
variant does not exert a switch mechanism for the corresponding
R123 (reviewed in [25]), it is thus likely that the mode of ALG-2
binding to Sec31A differs from that of Alix as previously suggested
[24]. Binding of Ca2+ to EF-hand 3 was described to cause an
increase in hydrophobic residue exposure, whereas binding of
Ca2+ to EF-hand 1 did not significantly change surface hydro-
phobicity [26]. Our findings show that binding of Ca2+ to EF hand
1 directs binding of ALG-2 to Sec31A (Figure 2A) and ALG-2/
Ca2+-dependent vesicle budding inhibition. Yamasaki et al.
showed that knockdown of Sec31A leads to removal of ALG-2
at the ER-exit site [3]. The retention kinetics of a fluorescently
tagged version of Sec31A changed upon removing the ALG-2-
binding site of Sec31A [18] indicating that ALG-2 affects the turn-
over of Sec31A at the ER-exit sites. We were able to restore ALG-
2/Ca2+ inhibited budding reactions on addition of a Ca2+
chelator, indicating that ALG-2 during Ca2+-transients attenuates
vesicle budding. ALG-2 could be functioning as a safeguard during
elevated cellular Ca2+ to ensure that COPII vesicles do not merge
directly with the Golgi apparatus as proposed by Bentley et al. [5],
but fuse to form ERGIC. Interestingly ALG-2 is conserved in
higher eukaryotes (reviewed in [27]) whereas yeast, which are
believed to be void of ERGIC, has a common ancestral penta-EF
hand (PEF) family protein. It is possible that ALG-2 has evolved in
higher eukaryotes in order to regulate sorting of proteins to
ERGIC. The PEF-family yeast homologue, Pef1p was recently
Figure 2. ALG-2 attenuates in vitro reconstituted COPII vesicle budding in a reversible manner. Budding investigated using p58/ERGIC
as a marker after incubation of HeLa cell donor membranes with recombinant Sar1A, Sec23A/24D, Sec13/31A and 0–2 ug of recombinant ALG-2. A.
Budding efficiency was measured at increasing concentrations of either ALG-2 or Ca2+. B. Attenuation of budding was dependent on EF hand 1 of
ALG-2. Binding of ALG-2 wildtype (wt) and mutants to Sec31A was tested by incubating either wt ALG-2 (wt), ALG-2.1 (2.1), ALG-2mutEF1 (EF-1), ALG-
2mutEF3 (EF-3) or ALG-2mutEF1&3 (EF-1–3) with Sec31A-coated beads. Eluates were separated by SDS-PAGE and visualized using SyproRed. C. In
vitro reconstituted budding using p58 as a budding marker. Mutant versions of ALG-2 were added to the budding reaction in equimolar amounts. D.
ALG-2/Ca2+ budding attenuation was reversed by chelation of Ca2+. In vitro reconstituted vesicle budding using p58 as a cargo protein marker.
Budding was performed for 45 min in the presence of Ca2+ only (control), Ca2+/ALG-2 (ALG-2) or in absence of nucleotides. EGTA was added to
budding reactions at T = 15 and T= 30 min and reactions were incubated in the presence of 1 mM EGTA for the indicated time periods (min).
Background budding levels were found by omitting nucleotides (no nuc). SEM of three independent experiments. E. 10–40% Nycodenz gradient was
layered on top of the product of the budding reactions performed in the absence (upper panel) or presence (lower panel) of recombinant ALG-2.
doi:10.1371/journal.pone.0075309.g002
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reported to bind to the Sec13/31p in a Ca2+-independent manner
[28]. We were not able to detect binding between Sec31A and the
mammalian homologues of Pef1p, Peflin (not shown). We propose
that the attenuation of the COPII budding process facilitates
transport of specific cargo in a Ca2+-dependent manner. Perhaps
ALG-2 acts to stall the budding process to synchronize cargo
sorting and vesicle morphogenesis. A role in cargo-dependent
regulation of export processes was recently discoverered for Sedlin,
a member of the TRAPP complex. Sedlin knockdown was shown
to specifically decrease procollagen packaging whereas neither
secretion of other tested proteins nor the trafficking of VSV-G was
affected. Sedlin directly interacted with Sar1 preferentially in its
GTP bound state presumably regulating Sar1 cycling at ER exit
sites and thereby the stability of membrane buds [29]. It is possible
that ALG-2 exerts a similar effect through Sec31A by regulating
the availability of Sec13/31A for the Sec31A/Sec23 interaction.
Previously it was shown that addition of cytosol enhanced the
recruitment of COPII proteins to membranes indicating that
cytosolic factors assist coat subunit recruitment or coat assembly
[15]. We find that ALG-2 facilitates the binding of Sec13/31A and
Sec23, although previous reports have shown that Sar1 in concert
with Sec23 is needed for interaction with Sec31 [30,31] and more
specifically bind an active fragment of Sec31A, which stimulates
the GAP activity of Sec23 [31]. Both the ALG-2 binding site and
the active fragment of Sec31A are situated in the proline-rich
region of Sec31 and it is possible that ALG-2 modulates this
domain to accommodate the Sec31A binding to Sec23. Perhaps
ALG-2 replaces the bridging effect of the active fragment and by
this inhibits GAP activity and vesicle release.
It is possible Ca2+/ALG-2 signals a cellular requirement to
arrest cargo transport vesicle budding during periods of ER stress
or other cellular processes where a protein export halt would be
advantageous. The recent discovery that monoubiquitination of
Sec31A is essential for collagen secretion in mouse embryonic stem
cells [14] opens for novel experimental approaches in concert with
the present discovery of an ALG-2/Ca2+-dependent attenuation of
vesicle budding. Furthermore, Sec31A phosphorylation and
membrane association was found to be regulated by casein kinase
2, which also affected ER to Golgi traffic [32]. Future work in this
field will be directed at investigating whether ALG-2/Ca2+
contributes to regulation of the formation of large COPII vesicles
through these postranslational modification processes. Aberrant
trafficking and enhanced surface expression of the T-cell receptor
could explain the apparent role of ALG-2 in promoting T-cell
receptor-mediated cell death [6]. Based on our previous research
we do not find a direct function of ALG-2 in apoptosis, rather a
Figure 3. Binding of ALG-2 to Sec31A attenuates COPII budding. A. Peptide array mapping of the ALG-2-binding domain (ABD) of Sec31A.
Binding efficiency of fluorescein tagged recombinant ALG-2 binding to 20-mer peptides (upper panel). Various lengths of the indicated proline rich
repeats were used as controls (lower panel) B. Diagram representing the ABD of Sec31A and the sequence removed from the Sec31aAdelABD. C.
Recombinant ALG-2 was incubated with Ni-beads alone, with purified His-tagged Sec13/Sec31A (wt) or Sec13/Sec31A with the ABD deleted (delABD)
in the presence of Ca2+. Proteins in the gel were visualized using SyproRed. D. Budding was performed using purified Sar1A, Sec23A/24D and either
wt Sec13/31A (wt) or Sec13/31A with the ABD of Sec31A deleted (delABD) in the presence of 0.15 ug ALG-2. Background budding levels were found
by omitting nucleotides (-nuc). Budding efficiency was normalized to the Sec13/31A wt and delABD respectively. SEM of three independent
experiments. E. Addition of excess (5 mg) ALG-2 inhibits vesicle budding independent of Sec31A.
doi:10.1371/journal.pone.0075309.g003
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necessity for ALG-2 in cell proliferation [33,34]. It could be that
the correct expression at the cell surface of certain growth
regulators depends on ALG-2 through its effect on ER to Golgi
trafficking. Experiments investigating the plasma membrane
proteome following elevated Ca2+-levels in the presence and
absence of ALG-2 will be important to further study the role of
ALG-2/Ca2+ in protein transport.
Materials and Methods
Buffers
Phosphate-buffered saline without calcium and magnesium
(PBS, pH 7.4) was purchased from Mediatech (Herndon, VA).
TBS contains 50 mM Tris-HCl (pH 7.4), 150 mM NaCl. TBST is
TBS supplemented with 0.1% (w/v) Tween 20. Buffer A
(budding): 20 mM HEPES-KOH (pH 7.4), 250 mM sorbitol,
150 mM potassium acetate; buffer B (protein purification): 20 mM
HEPES-KOH (pH 8.0), 10% (w/v) glycerol, 250 mM sorbitol,
500 mM potassium acetate, 0.1 mM EGTA, 5 mM ß-mercapto-
ethanol, 10 mM imidazole; buffer C (protein purification): 20 mM
HEPES-KOH (pH 8.0), 10% (w/v) glycerol, 250 mM sorbitol,
0.1 mM EGTA, 5 mM ß-mercaptoethanol, 10 mM imidazole;
buffer D (protein purification): Buffer B with 50 mM imidazole;
buffer E (protein purification): Buffer B with 250 mM imidazole;
buffer F (Liposome flotation): 20 mM HEPES-KOH (pH 6.8),
110 mM potassium acetate, and 2 mM MgCl2; buffer G (M2
immunoprecipitation): Buffer A with 0.1% NP40 and 100 mM
CaCl2. Buffer H consists of 150 mM Tris-HCl (pH 6.8), 15% (w/
Figure 4. Sec31A is recruited to liposomes and Sec23 in an ALG-2-dependent manner. A. Recombinant proteins bound to artificial
liposomes and collected from a sucrose gradient were analyzed for recruitment efficiency in the presence of ALG-2 and a peptide representing the
ABD (pABD). Antibodies directed against Sec31A, HA tag (HA-Sec13), Flag-tag (flag-Sec23A), Sar1 and ALG-2 were used to analyze protein
recruitment. The immunoblot is representative of more than three independent experiments. B. Quantification of band intensities relative to Ca2+
control (ctr) in representative immunoblot. C. Anti-Flag antibody coated beads were used as bait for flag-Sec23. Protein binding was performed in
the presence of Ca2+ and proteins in gels were visualized using SyproRed staining.
doi:10.1371/journal.pone.0075309.g004
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v) SDS, 25% (w/v) glycerol, 0.02% (w/v) bromphenol blue, and
12.5% (w/v) 2-mercaptoethanol. Buffers A–H were added EDTA-
free protease inhibitor mix from Roche (Roche).
Mapping of Sec31A ALG-2-binding Site
The ALG-2 binding sequence of human Alix/AIP1 was used in
silico to find the most probable binding motif of Sec31A.
Overlapping peptides (20-mer) representing amino acids 808–
869 were synthesized on a nitrocellulose membrane as previously
described [35] and overlaid with fluorescein labeled recombinant
ALG-2 (0.2 mg/ml) in a buffer containing 50 mM Tris-HCl,
pH 7.5, 0.5% BSA, 0.05% Tween 20, 0.15 M NaCl, 0.3 M
arginine and either 1 mM CaCl2 or 5 mM EDTA. Spot
intensities were measured using a Typhoon scanner.
Construction of the ALG-2-binding Deficient Sec31A
Deletion of the ALG-2 binding site corresponding to amino
acids 827–852 of human Sec31A was carried out using forward
and reverse primers 23 bp upstream and downstream of the
deleted sequence. Two PCR reactions were carried out in parallel,
one with the forward primer in combination with a primer
containing a unique Eco47III site in the Sec31 sequence and the
forward primer with a unique Spe1 site in the plasmid sequence.
The PCR products were mixed and used as primers and templates
in a second PCR reaction. The PCR product was then cut with
the two enzymes and cloned back into the vector. Sequencing
confirmed the correct deletion.
Protein Purification
Recombinant ALG-2 was purified as previously described [16].
Mammalian COPII proteins were inserted in the Bac-to-Bac
baculovirus expression system (Invitrogen) and purified in
accordance with procedures described in [36]. In brief pHA-
Sec23A/B, and pHis-Sec24A/B/C/D were co-expressed as was
pHA-Sec13 and either pHis-Sec31A or pHis-Sec31ADelABD in
ES-SF9 cells. Human GST-Sar1 WT and H79G were purified
from Escherichia coli as described [15]. FLAG-Sec23/His-Sec24 and
HA-Sec13/His-Sec31 complexes were purified using Ni-NTA
affinity chromatography as described in [36].
In vitro Vesicle Budding Assay
The vesicle budding assay was performed as described
previously [37]. In brief, HeLa cells were harvested in PBS and
permeabilized by 5 min incubation in Buffer F containing 40 mg/
ml digitonin. Permeabilized cells were washed in Buffer A and
used at 40 ug protein/reaction. The budding reaction was
assembled using either rat liver cytosol at 4 mg/ml or purified
Sar1A/B, HA-Sec13/His-Sec31A and Flag-Sec23A/His-Sec24D.
Unless otherwise stated, an ATP-regenerating system was added
resulting in final concentrations of 1 mM ATP, 40 mM creatine
phosphate, 0.2 mg/ml creatine phosphokinase and 0.1 mM GTP.
Unless otherwise stated, 0.3 mg rALG-2 was added to reactions
when indicated. Budding reactions were assembled on ice and
incubated for 30 min at 30uC then put on ice. The donor
membranes were removed by a 20 min 12,0006g centrifugation
and the supernatant fraction was further centrifuged for 25 min at
55,000 rpm at 4uC using a TLA100 rotor in a Beckman Optima
TLX ultracentrifuge to sediment the vesicle products. To
fractionate the budding vesicles by flotation, we mixed the
budding reaction 1:1 with 80% (w/v) Nycodenz (Progen) in buffer
A. The reaction was overlaid with a gradient of 35-10% Nycodenz
in buffer A and centrifuged for 2 h at 55,000 rpm in a TLS-55
rotor. Fractions were collected from the top and mixed with Buffer
H for separation by SDS-PAGE and immunoblot analysis.
Liposome Flotation Assay
Detailed procedures for the liposome-binding assay were
described in Matsuoka and Schekman [38]. The liposomes were
prepared from a liposome mix containing 31.8 mM dioleoylpho-
sphatidylcholine, 33.6 mM dioleoylphosphatidylethanolamine,
12.3 mM dioleoylphosphatidylserine, 13.9 mM dioleoylphospha-
tidic acid, 11.7 mM phosphotidylinositol, 5.0 mM phosphotidyli-
nositol phosphate, 4.6 mM phosphotidylinositol bisphosphate,
4.8 mM cytidine diphosphate diacylglycerol, 0.7 mM Texas Red
phosphotidylethanolamine (TX-PE, Molecular probes). A lipo-
some suspension (20 ml) was mixed with 1.6 mg of Sar1A, 1.7 mg of
Sec23A/24D, 2 mg of Sec13/31A, 100 mM GTPcS and up to
80 ml of HKM buffer was added following addition of ALG-2,
pSec31AdelABD, Ca2+ and EGTA as stated in Figure 4. Binding
was performed for 30 min at 30uC and the liposome/protein
solution was mixed with 50 ml 2.5 M sucrose in HKM buffer
followed by overlaying first with 100 ml 0.75 M sucrose in HKM
and then with 20 ml HKM. Following a 20 min centrifugation at
100,000 rpm using a TLA100 rotor, the top fraction was collected
and loaded on a gel normalized to TX-PE fluorescence.
Sec23 Binding
Anti-Flag M2 (Sigma-Aldrich) affinity gel was washed twice with
Buffer G and 4 mg Flag-Sec23/His-Sec24 complexes per reaction
were immobilized on the matrix and incubated for 20 min at 4uC.
Sec13/31A (5 mg) or Sec13/31AdelABD were added to the matrix
along with 0.3 mg rALG-2. Proteins were incubated with matrix
for at least 2 h at 4uC before three washes of matrix in Buffer G.
Bound proteins were eluted using 0.25 mg/ml Flag peptide in
Buffer G.
Antibodies
Polyclonal antibodies against ALG-2 were as previously
described [39]. Monoclonal antibodies against the His-tag
(Penta-His) and Sec31A (clone 32) were purchased from Qiagen
and BD Biosciences, respectively. Detection by immunoblot
analysis using polyclonal anti-ERGIC-53, anti-Ribophorin-I,
anti-Sec22b, and Sar1 rabbit antiserum was performed as
previously described [37].
Protein Visualization
Proteins were resolved on 10% or 4–20% gradient SDS gels and
either transferred to PVDF membranes by wet electroblotting
followed by visualization using the LI-COR infared imaging
system (Li-cor Biosciences) or stained with SYPROred (1:5000,
Invitrogen) in 7.5% acetic acid and scanned in a Typhoon (GE
Life Sciences). Quantification of protein intensities was performed
using either the Odyssey or ImageJ image analysis software.
Supporting Information
Figure S1 Buoyant budded vesicles containing p58/
ERGIC do not contain ALG-2. The product of vesicle budding
reactions performed with or without recombinant ALG-2 was
resolved in a 10–40% Nycodenz gradient and fractions were
analyzed for the presence of p58, Sec31A and ALG-2. The right
hand side input lanes were run on separate gels.
(EPS)
Figure S2 Titration of recombinant COPII proteins for
quantification of liposome binding. 10–200 ng of recombi-
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nant proteins were analyzed following SDS-PAGE and Western
blot analysis using the antibodies described in materials and
methods.
(EPS)
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